Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
cancer
deals
diagnostics
medicare
merck
pfizer
startups
abbvie
amgen
biogen
cancer immunotherapy
What
bio
5
×
drug
5
×
roundup
acquisitions
biggest
ceo
companies
new
patients
plan
price
advantages
albert
alzheimer’s
approval
bar
biogen’s
biopharmaceutical
bourla
brings
build
buy
company
company’s
convo
crispr
daniel
debut
different
dyne’s
earlier
expect
fail
failures
future
gamble
gene
gilead
imports
increases
Language
unset
unknown
Current search:
drug
×
biotech
×
bio
×
novartis
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More